

**Question for written answer E-003302/2016  
to the Commission**

Rule 130

**Claudiu Ciprian Tănăsescu (S&D)**

Subject: Access to medicines

One of the biggest problems facing EU healthcare systems is restricted access to appropriate treatments and medicines for patients. In this context, I would like to ask the Commission what steps are being taken to:

1. increase genuine innovation on the market and encourage the development of paediatric medicines and of new drugs that have a real therapeutic benefit in comparison with the best alternatives already on the market;
2. find appropriate means to enable patients to pay for medicines just once rather than twice, as is currently the case on account of the public funding of medical research and development; and
3. encourage a harmonised approach to the assessment of medicines in the Member States.